- Home
- NBTX vs ALVO Comparison
NBTX vs ALVO Comparison
Compare NBTX & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBTX | ALVO |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | France | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | NBTX | ALVO |
|---|---|---|
| Price | $49.33 | $3.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $36.00 | $8.00 |
| AVG Volume (30 Days) | 71.3K | ★ 390.4K |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.17 | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.64 | $3.03 |
| 52 Week High | $57.14 | $11.85 |
Technical Indicators
Market Signals| Indicator | NBTX | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 62.43 | 42.80 |
| Support Level | $19.22 | $3.10 |
| Resistance Level | N/A | $3.83 |
| Average True Range (ATR) | 3.37 | 0.20 |
| MACD | 1.29 | -0.00 |
| Stochastic Oscillator | 70.98 | 13.27 |
Price Performance
Historical ComparisonAbout NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.